Wedbush reissued their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX - Free Report) in a research report released on Thursday morning,RTT News reports. The brokerage currently has a $31.00 target price on the stock.
Several other brokerages also recently commented on BCAX. Cantor Fitzgerald restated an "overweight" rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $36.50.
Check Out Our Latest Stock Report on BCAX
Bicara Therapeutics Stock Performance
Shares of Bicara Therapeutics stock traded down $0.37 during trading on Thursday, reaching $13.03. The company's stock had a trading volume of 559,438 shares, compared to its average volume of 467,529. The firm's 50-day moving average price is $13.04. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). Equities research analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.
Institutional Trading of Bicara Therapeutics
A number of hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $25,000. Spire Wealth Management purchased a new stake in Bicara Therapeutics during the fourth quarter valued at about $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at approximately $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth $33,000. Finally, Summit Investment Advisors Inc. purchased a new stake in Bicara Therapeutics during the 4th quarter worth about $35,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
